Close Menu

Breaking News

The study suggested that ALL glucocorticoid resistance stemming from alterations that drive down CELSR2 levels might be combated with the BCL2-targeting drug venetoclax.

The Department of Health and Human Services selected the diagnostic test for development support through a streamlined process called an easy broad agency announcement.

The insurer will cover testing at the Rady Children's Institute for Genomic Medicine for children in intensive care with unexplained medical conditions.

Last week, GenomeWeb's readers were most interested in Thermo Fisher Scientific's plan to acquire Qiagen for $11.5 billion.

The firm said it saw "significant deterioration" in February due to "ongoing and protracted" disruptions resulting from the novel coronavirus and an extended Lunar New Year holiday.

The technology uses photostable and bright phosphor-integrated dots for quantitative, amplification-free detection of proteins at cellular and subcellular levels.

Genomica, a PharmaMar Group company, has developed kits based on real-time PCR and its CLART low-density microarray technology.

The companies have agreed to combine their respective offerings into a single services package for drug target identification and validation.

News items for the week of March 2, 2020. 

Hologic said laboratories may leverage the random-access and open-access capabilities of its Panther Fusion system to broaden screening for the novel coronavirus.

LabCorp's test is being made available pursuant to FDA guidance that allows high-complexity, CLIA-certified labs to perform their own tests for SARS-CoV-2.

The company said clinical services revenues and diagnostic testing volumes rose during the quarter, but that PAMA continued to negatively affect reimbursements.

Under the terms of the non-exclusive agreement, the companies have made Diagenode's D-Plex library preparation products available on MGI's sequencing platforms.

The genome mapping firm's instrument revenues were down 50 percent year over year in the fourth quarter, offset by an increase in consumables revenue.

A genetic analysis based on more than 32,000 individuals living in the US traced the ancestry, historical migration, and other patterns present in populations around the country.

A retrospective cohort study uncovered microRNA signatures that could tell lung cancer patients apart from others, including patients with other, non-tumor lung conditions.

SARS-CoV-2 viral material is available for test validation, and the FDA is conducting a rolling review process with an abbreviated submission template.

The Belgian diagnostics company said it has partnered with Bristol-Myers Squibb to register its MSI test as a companion diagnostic in China. 

The company intends to use most of the proceeds to pay off debts and associated fees, and the rest to support its platform and consumables development. 

The company expects that proceeds from this transaction, combined with another direct offering earlier this week and its current cash reserve, can support operations through the end of this year.

The assay detects 10 STIs and is performed on the molecular point-of-care Vivalytic platform, which was codeveloped by German company Bosch.

The consortium aims to develop assays that can detect biomarkers of pulmonary fibrosis that can be used as early indicators of a treatment's activity.

UK-based Abcam has acquired Oregon-based life science research tool provider Marker Gene Technologies, the latest in a string of asset purchases.

Pages

Retraction Watch writes that a cancer researcher has had an eighth paper retracted.

Computational biologist James Taylor has died, according to Johns Hopkins University.

The Centers for Disease Control and Prevention is starting to test people for SARS-CoV-2 antibodies, according to the New York Times.

In PLOS this week: features of tumor-infiltrating immune cells, regulatory effects of SNPs associated with prostate cancer risk, and more.